sulfathiazole

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	0.104		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	1.862		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	19.498	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	2.307	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	35.100	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	45.580	%	High	1
herg	hERG pIC50	4.025	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	2.028	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	3.793	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	24.830	%	High	1
kinase-safety-class	ACVR2A,ACVR2B,AKT3,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK1,JAK2,MAP2K6,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAPK12,MAPK7,MAPK9,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1	54
kinase-selectivity-class	ACVR2A,AURKA,AXL,CDK1,CDK9,DDR1,DYRK1B,EPHB4,ERBB2,GRK2,JAK1,MAP2K3,MAP2K6,MAP3K7,MAP4K1,MAPK12,MAPK7,MARK4,PDK4,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1	28
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	1.807		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	4.603		High	1
mppb	Mouse plasma protein binding (% unbound)	42.850		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	1.905		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	33.440	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	1.679	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	92.340	%	High	1
rppb	Rat plasma protein binding (% unbound)	17.090	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	939.723	uM	High	1

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Subcutaneous drug absorption impaired	253.25	81.63	105	23920	13440	90590982
General symptom	241.88	81.63	104	23921	14564	90589858
Rash vesicular	223.47	81.63	105	23920	18092	90586330
Breast cancer stage II	221.62	81.63	130	23895	35204	90569218
Pustular psoriasis	218.46	81.63	104	23921	18452	90585970
Back disorder	211.70	81.63	113	23912	25518	90578904
Myositis	209.55	81.63	110	23915	24018	90580404
Dislocation of vertebra	180.46	81.63	136	23889	55832	90548590
Adjustment disorder with depressed mood	178.77	81.63	136	23889	56617	90547805
Folliculitis	148.74	81.63	224	23801	204129	90400293
Wound infection	146.27	81.63	160	23865	106242	90498180
Hypocholesterolaemia	144.66	81.63	57	23968	6392	90598030
X-ray abnormal	138.97	81.63	107	23918	45317	90559105
Joint range of motion decreased	135.12	81.63	173	23852	135470	90468952
Irritable bowel syndrome	130.94	81.63	213	23812	207235	90397187
Anti-cyclic citrullinated peptide antibody positive	129.68	81.63	228	23797	236205	90368217
Muscle injury	123.35	81.63	190	23835	176464	90427958
Disability	122.50	81.63	95	23930	40650	90563772
Impaired healing	122.21	81.63	221	23804	233978	90370444
Wound	121.72	81.63	256	23769	302724	90301698
Pericarditis	118.82	81.63	237	23788	269914	90334508
Blood cholesterol increased	118.48	81.63	204	23821	207808	90396614
Hypercholesterolaemia	117.09	81.63	139	23886	100753	90503669
Swollen joint count increased	115.75	81.63	145	23880	111061	90493361
Lower respiratory tract infection	111.53	81.63	221	23804	250438	90353984
Rheumatoid factor positive	107.93	81.63	176	23849	171474	90432948
Drug ineffective	105.36	81.63	128	23897	1384170	89220252
Liver injury	103.35	81.63	172	23853	170395	90434027
Pemphigus	103.17	81.63	251	23774	326613	90277809
Peripheral venous disease	103.00	81.63	119	23906	83802	90520620
Glossodynia	101.46	81.63	247	23778	321532	90282890
Rheumatic fever	98.98	81.63	159	23866	152962	90451460
Helicobacter infection	97.29	81.63	197	23828	226653	90377769
Grip strength decreased	95.19	81.63	120	23905	92456	90511966
Type 2 diabetes mellitus	92.55	81.63	181	23844	203063	90401359
Duodenal ulcer perforation	92.32	81.63	190	23835	221098	90383324
Blister	91.54	81.63	206	23819	254792	90349630
Fluid retention	90.27	81.63	114	23911	87977	90516445
Walking aid user	90.16	81.63	75	23950	35431	90568991
Ill-defined disorder	89.50	81.63	169	23856	184722	90419700
Synovitis	89.28	81.63	239	23786	329513	90274909
Psoriatic arthropathy	85.93	81.63	188	23837	228147	90376275
Memory impairment	85.39	81.63	172	23853	197072	90407350
Fall	85.30	81.63	13	24012	481797	90122625
Amnesia	84.68	81.63	123	23902	108382	90496040
Hand deformity	84.49	81.63	219	23806	296143	90308279
Migraine	83.58	81.63	167	23858	190225	90414197
Pulmonary fibrosis	82.64	81.63	121	23904	107382	90497040
Delirium	82.46	81.63	119	23906	104240	90500182
Lupus vulgaris	82.28	81.63	79	23946	44980	90559442

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypocholesterolaemia	177.57	86.65	57	16262	6364	110566616
Peripheral venous disease	165.02	86.65	120	16199	83997	110488983
Breast cancer stage II	154.17	86.65	77	16242	27298	110545682
Lupus vulgaris	146.98	86.65	80	16239	33803	110539177
Adjustment disorder with depressed mood	137.93	86.65	84	16235	43799	110529181
General symptom	137.31	86.65	51	16268	8795	110564185
Subcutaneous drug absorption impaired	136.90	86.65	49	16270	7610	110565370
Dislocation of vertebra	135.66	86.65	83	16236	43638	110529342
Bursitis	134.56	86.65	128	16191	129790	110443190
Wound infection	131.50	86.65	111	16208	96354	110476626
Folliculitis	129.55	86.65	141	16178	167512	110405468
Wound	124.76	86.65	163	16156	234274	110338706
Back disorder	121.21	86.65	60	16259	20862	110552118
Joint range of motion decreased	120.42	86.65	117	16202	121715	110451265
Bone erosion	118.81	86.65	78	16241	46293	110526687
Taste disorder	116.36	86.65	88	16231	65299	110507681
Pemphigus	115.42	86.65	150	16169	214420	110358560
Breast cancer stage III	113.95	86.65	94	16225	79023	110493957
Pericarditis	112.94	86.65	150	16169	218964	110354016
Glossodynia	112.93	86.65	151	16168	221853	110351127
Irritable bowel syndrome	107.93	86.65	127	16192	164088	110408892
Anti-cyclic citrullinated peptide antibody positive	106.99	86.65	133	16186	181851	110391129
Pustular psoriasis	106.44	86.65	48	16271	13557	110559423
Rash vesicular	106.15	86.65	49	16270	14603	110558377
Exostosis	105.01	86.65	72	16247	45884	110527096
Impaired healing	104.97	86.65	137	16182	196580	110376400
Blepharospasm	104.70	86.65	77	16242	54774	110518206
Night sweats	102.27	86.65	112	16207	133871	110439109
Musculoskeletal pain	101.62	86.65	130	16189	182893	110390087
Retinitis	96.78	86.65	60	16259	32267	110540713
Psoriatic arthropathy	94.22	86.65	130	16189	196631	110376349
Type 2 diabetes mellitus	93.87	86.65	123	16196	177109	110395871
Liver injury	93.36	86.65	113	16206	150300	110422680
Nail disorder	92.24	86.65	73	16246	57862	110515118
Product quality issue	91.31	86.65	82	16237	77217	110495763
Laryngitis	91.16	86.65	64	16255	42347	110530633
X-ray abnormal	87.75	86.65	60	16259	38057	110534923
Hypercholesterolaemia	87.42	86.65	86	16233	90751	110482229

Source	Code	Description
ATC	D06BA02	DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE CHEMOTHERAPEUTICS FOR TOPICAL USE Sulfonamides
ATC	J01EB07	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Short-acting sulfonamides
MeSH PA	D000890	Anti-Infective Agents
CHEBI has role	CHEBI:33282	antibacterial agent
CHEBI has role	CHEBI:35441	antiinfective agent
CHEBI has role	CHEBI:35703	xenobiotic
CHEBI has role	CHEBI:50502	EC 2.5.1.15 (dihydropteroate synthase) inhibitor
CHEBI has role	CHEBI:78298	environmental contaminant
CHEBI has role	CHEBI:88188	drug allergen

Disease	Relation	SNOMED_ID	DOID
Vulvovaginitis	indication	53277000	DOID:2273
Gardnerella Vaginalis Bacterial Vaginosis	indication
Kidney disease	contraindication	90708001	DOID:557
Anemia due to enzyme deficiency	contraindication	111577008
Deficiency of glucose-6-phosphate dehydrogenase	contraindication	124134002	DOID:2862
Disease of blood AND/OR blood-forming organ	contraindication	191124002	DOID:74
Disease of liver	contraindication	235856003	DOID:409
Breastfeeding (mother)	contraindication	413712001
Porphyria	contraindication	418470004

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

sulfathiazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Endothelin-1 receptor	GPCR	P25101	EDNRA_HUMAN		IC50	4.16	WOMBAT-PK
Dihydropteroate synthase	Enzyme		DHPS_ECOLI	INHIBITOR	IC50	5.60	CHEMBL	CHEMBL
Endothelin-1 receptor	GPCR		EDNRA_RAT		IC50	4.16	CHEMBL
Transcriptional activator protein LasR	Transcription factor		LASR_PSEAE		IC50	5.05	CHEMBL

ID	Source
4018558	VUID
N0000178992	NUI
D01047	KEGG_DRUG
4018558	VANDF
C0038722	UMLSCUI
CHEBI:9337	CHEBI
YTZ	PDB_CHEM_ID
CHEMBL437	ChEMBL_ID
DB06147	DRUGBANK_ID
D000077589	MESH_DESCRIPTOR_UI
5340	PUBCHEM_CID
12699	IUPHAR_LIGAND_ID
428	INN_ID
Y7FKS2XWQH	UNII
10193	RXNORM
5529	MMSL
002815	NDDF
16867004	SNOMEDCT_US
387093005	SNOMEDCT_US

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.16	acidic
pKa2	2.48	Basic
pKa3	1.61	Basic